Larotrectinib (LOXO-101), a highly selective pan-TRK inhibitor, was first evaluated in a study of 55 pediatric and adult patients with various TRK fusion-positive malignancies, four of whom had lung cancer, and reported an ORR of 75% [10]. This evidence concerns the gene NTRK1 and lung carcinoma.